Lupin Pharmaceuticals announced that it has received final FDA approval for Pregabalin Capsules, the generic version of Pfizer‘s Lyrica capsules.

Lyrica, an α2-delta ligand, is indicated for neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, and as adjunctive therapy for adult patients with partial onset seizures and fibromyalgia. Lyrica works by slowing down impulses in the brain that cause seizures. It also affects chemicals in the brain that send pain signals across the nervous system.

Pregabalin Capsules will be available from Lupin in 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg dosage strength capsules.

For more information call (866) 587-4617 or visit